Achillion Pharmaceuticals


Stock Update (NASDAQ:ACHN): Achillion Pharmaceuticals, Inc. Announces Upcoming Presentations at the International Liver Congress 2015 (EASL)

Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) announced that it will present three posters, including two late breaker abstracts, at the 50th Annual Meeting of the …

Achillion Pharmaceuticals Stock Soars Following Successful Mid-Stage Hep C Drug Combo Trial

Shares of Achillion Pharmaceuticals (NASDAQ: ACHN) jumped almost 20% in trading on February 9th after the company announced positive interim data results for its hepatitis …

Maxim Reiterates Buy On Achillion Following Successful Mid-Stage Hep C Drug Combo Trial

In a research report issued today, Maxim Group analyst Jason Kolbert reiterated a Buy rating on Achillion Pharmaceuticals (NASDAQ:ACHN) with a $22 price target, as …

UPDATE: Cowen Maintains Outperform On Achillion Pharmaceuticals Following ACH-3102 Interim Data

Cowen’s healthcare analyst Phil Nadeau is weighing in with a few insights on Achillion Pharmaceuticals (NASDAQ:ACHN), following new trial results which demonstrated that a combination of the …

We Remain Positive And Consistent With Our Bullish Investment Thesis On Achillion, Says Maxim

In a research report issued today, Maxim Group analyst Jason Kolbert reiterated a Buy rating on Achillion Pharmaceuticals (NASDAQ:ACHN) with a $22 price target, …

Maxim Remains Bullish On Achillion Pharmaceuticals, Sees 59% Upside

In a research report released Monday, Maxim Group analyst Jason Kolbert reiterated a Buy rating on Achillion Pharmaceuticals (NASDAQ:ACHN) with a $22 price …

Maxim Maintains Buy On Achillion Pharmaceuticals Following 3Q14 Update

In a research report issued today, Maxim Group analyst Jason Kolbert maintained a Buy rating on Achillion Pharmaceuticals (NASDAQ:ACHN) with a $22 price …